ALNY Financial Facts
Loss from operations: -92.45MComprehensive loss: -109.41M
See Full Income Statement
Total liabilities and stockholders' equity: 1.38B
Accumulated other comprehensive (loss) income: -28.3M
See Full Balance Sheet
Alnylam Pharmaceuticals, Inc. (ALNY) Earnings
|
Expand Research on ALNY
| Next EPS Date | 5/2/24 | EPS Growth Rate | -7.5% |
|---|---|---|---|
| Average EPS % Beat Rate | +75.3% | Revenue Growth Rate | +33.0% |
| Average % Move 1-Wk after EPS | +1.9% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/2/23 | Q323 | $1.74 | -$1.32 | +$3.06 | $750.5M | $397.99M | N/A |  | | Details | |
| 2/15/24 | Q423 | -$0.77 | -$1.26 | +$0.49 | $439.72M | $436.08M | = | | | Details | |
| 2/23/23 | Q422 | -$1.39 | -$1.85 | +$0.46 | $335.04M | $312.2M | N/A | | | Details | |
| 5/4/23 | Q123 | -$1.06 | -$1.68 | +$0.62 | $319.29M | $312.27M | N/A | | | Details | |
| 8/3/23 | Q223 | -$1.62 | -$1.52 | -$0.10 | $318.75M | $332.83M | N/A | | | Details | |
| 10/27/22 | Q322 | -$1.58 | -$1.73 | +$0.15 | $264.3M | $293.08M | = | | | Details | |
| 2/10/22 |  |
Q421 | -$1.69 | -$1.56 | -$0.13 | $258.5M | $231.44M | = | | | Details |
| 7/28/22 | Q222 | -$2.03 | -$1.61 | -$0.42 | $224.82M | $255.87M | = | | | Details |
